FDA Nonprescription Office Expects Progress On Sunscreen Monograph
This article was originally published in The Rose Sheet
Executive Summary
With added expertise in the FDA's Division of Nonprescription Regulation Development, the division aims to make headway on the long-delayed OTC sunscreen monograph
You may also be interested in...
FDA Proposes September Deadline For Sunscreen Rule...And May Stick To It
Meeting proposed deadlines on regulatory agenda actions, such as finalizing OTC monographs, could be a higher priority for FDA under its new management
FDA Proposes September Deadline For Sunscreen Rule...And May Stick To It
Meeting proposed deadlines on regulatory agenda actions, such as finalizing OTC monographs, could be a higher priority for FDA under its new management
Industry, Docs And Congress Combine Voices In Call For Final Sunscreen Regs
Stakeholders have teamed up to light a fire under FDA, frustrated with the agency's lack of progress in making state-of-the-art, broad-spectrum sunscreens available to Americans